Evolus (NASDAQ:EOLS) Insider David Moatazedi Sells 105,108 Shares

Evolus, Inc. (NASDAQ:EOLS) insider David Moatazedi sold 105,108 shares of the company’s stock in a transaction on Wednesday, September 2nd. The stock was sold at an average price of $9.04, for a total transaction of $950,176.32. Following the transaction, the insider directly owned 499,592 shares in the company, valued at approximately $4,516,311.68. This trade represents a 17.38% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Evolus Stock Up 2.8%

Shares of EOLS stock opened at $9.30 on Friday. Evolus, Inc. has a fifty-two week low of $3.86 and a fifty-two week high of $9.31. The business has a fifty day simple moving average of $7.26 and a 200-day simple moving average of $6.08. The stock has a market cap of $614.26 million, a P/E ratio of -17.88 and a beta of 1.42.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on EOLS. Wall Street Zen upgraded shares of Evolus from a “hold” rating to a “buy” rating in a research report on Saturday, August 8th. HC Wainwright reiterated a “buy” rating and issued a $13.00 price target on shares of Evolus in a research report on Tuesday, August 25th. BTIG Research reissued a “buy” rating and set a $13.00 price objective on shares of Evolus in a research note on Wednesday, June 17th. Finally, Weiss Ratings upgraded Evolus from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday, June 15th. Four equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Evolus presently has a consensus rating of “Moderate Buy” and a consensus price target of $14.50.

Hedge Funds Weigh In On Evolus

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Rhumbline Advisers boosted its holdings in shares of Evolus by 2.0% in the 2nd quarter. Rhumbline Advisers now owns 85,093 shares of the company’s stock valued at $784,000 after purchasing an additional 1,657 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in shares of Evolus by 5.8% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 33,289 shares of the company’s stock worth $400,000 after buying an additional 1,838 shares during the last quarter. Invesco Ltd. increased its holdings in shares of Evolus by 7.5% during the 2nd quarter. Invesco Ltd. now owns 34,283 shares of the company’s stock worth $316,000 after buying an additional 2,383 shares during the last quarter. California State Teachers Retirement System raised its position in shares of Evolus by 79.9% in the 2nd quarter. California State Teachers Retirement System now owns 5,455 shares of the company’s stock worth $38,000 after buying an additional 2,423 shares during the period. Finally, Larson Financial Group LLC raised its position in shares of Evolus by 136.6% in the 4th quarter. Larson Financial Group LLC now owns 4,914 shares of the company’s stock worth $33,000 after buying an additional 2,837 shares during the period. Institutional investors and hedge funds own 90.69% of the company’s stock.

About Evolus

Evolus, Inc is a specialty pharmaceutical company focused on medical aesthetics. Headquartered in Newport Beach, California, Evolus develops and commercializes products designed to enhance facial appearance through minimally invasive procedures. Since its founding in 2017, the company has positioned itself in the fast-growing aesthetic market by partnering with leading manufacturers and leveraging clinical expertise to bring innovative injectables to practitioners and patients.

The company’s flagship offering, Jeuveau (prabotulinumtoxinA-xvfs), is a neuromodulator approved by the U.S.